Over $250 Billion in Bonds Are at Risk
Aaron Levitt
|
For investors, the wipe-out of CoCo bonds brings forth a variety of questions...
Shares of Tekmira Pharmaceuticals (TKMR) have been surging as the company is now in clinical trials to create a drug for the virus. The company has been given approval by the FDA to give its TKM-Ebola drug to subjects “with confirmed or suspected Ebola virus infections.”
The recent U.S. case of Ebola in the U.S. also now has pharmaceutical companies racing to create a vaccine for the virus.
The companies involved in the treatment or vaccination of the virus range from small biotech companies to pharma giants like GlaxoSmithKline (GSK).
Ticker | Mutual Fund | Exposure | % of Shares Owned |
---|---|---|---|
FBDIX | Franklin Biotechnology Discovery A | Tekmira Pharmaceuticals (TKMR) | 3.15% |
SHSAX | BlackRock Health Sciences Opps Inv A | Tekmira Pharmaceuticals (TKMR) | 1.53% |
FBIOX | Fidelity Select Biotechnology Portfolio | NewLink Genetics Corp (NLNK) | 5.93% |
There are several mutual funds that offer specific exposure to these industries including the funds listed above.
Receive email updates about best performers, news, CE accredited webcasts and more.
Aaron Levitt
|
For investors, the wipe-out of CoCo bonds brings forth a variety of questions...
Aaron Levitt
|
One of the biggest and most important positions of the bill deals with...
News
Markets have continued to rally these past two weeks, after the Federal Reserve...
Mutual Fund Education
Justin Kuepper
|
Let's take a closer look at how ESG investments have outperformed during the...
Mutual Fund Education
Daniel Cross
|
While CITs and mutual funds share many similarities, there are some key differences...
Mutual Fund Education
Sam Bourgi
|
The phrase ‘bear market’ has been thrown around a lot lately, but it...
Shares of Tekmira Pharmaceuticals (TKMR) have been surging as the company is now in clinical trials to create a drug for the virus. The company has been given approval by the FDA to give its TKM-Ebola drug to subjects “with confirmed or suspected Ebola virus infections.”
The recent U.S. case of Ebola in the U.S. also now has pharmaceutical companies racing to create a vaccine for the virus.
The companies involved in the treatment or vaccination of the virus range from small biotech companies to pharma giants like GlaxoSmithKline (GSK).
Ticker | Mutual Fund | Exposure | % of Shares Owned |
---|---|---|---|
FBDIX | Franklin Biotechnology Discovery A | Tekmira Pharmaceuticals (TKMR) | 3.15% |
SHSAX | BlackRock Health Sciences Opps Inv A | Tekmira Pharmaceuticals (TKMR) | 1.53% |
FBIOX | Fidelity Select Biotechnology Portfolio | NewLink Genetics Corp (NLNK) | 5.93% |
There are several mutual funds that offer specific exposure to these industries including the funds listed above.
Receive email updates about best performers, news, CE accredited webcasts and more.
Aaron Levitt
|
For investors, the wipe-out of CoCo bonds brings forth a variety of questions...
Aaron Levitt
|
One of the biggest and most important positions of the bill deals with...
News
Markets have continued to rally these past two weeks, after the Federal Reserve...
Mutual Fund Education
Justin Kuepper
|
Let's take a closer look at how ESG investments have outperformed during the...
Mutual Fund Education
Daniel Cross
|
While CITs and mutual funds share many similarities, there are some key differences...
Mutual Fund Education
Sam Bourgi
|
The phrase ‘bear market’ has been thrown around a lot lately, but it...